Home
Faculty
Research Training
Opportunities
NIH Training Grant
Patient Care
Injury Prevention
Program
Alcohol Research
Program
Newsletter/Events
Department of
Surgery
Loyola University
Health System
Medical School

The Burn and Shock
Trauma Institute
Loyola University
Medical Center
2160 S. First Avenue
Maywood, IL 60153
USA
Phone: 708-327-2446
FAX: 708-327-2813

email:  bsti@lumc.edu

 

 

 

Loyola University Health System

Faculty Matthias Majetschak, M.D., Ph.D.
 

Assistant Professor, Department of Surgery and

The Burn & Shock Trauma Institute
M.D., Ph.D., University of Essen, Germany

Interests:  Intra- and extracellular functions of the ubiquitin proteasome system after injury and during inflammation

 
The ubiquitin proteasome pathway of protein degradation is the principal non-lysosomal proteolytic system in all eukaryotic cells and intimately involved in the regulation of protein function and quality control. In addition, covalent modification of proteins with ubiquitin (=ubiquitylation) is the second most common posttranslational modification following phosphorylation. Ubiquitylation either labels the target protein for degradation by the 26S proteasome or reversibly regulates the target protein’s function. Current research in Dr. Majetschak’s laboratory is focused on the role of the intracellular ubiquitin proteasome pathway during the local and systemic response to injury and infection, and on unconventional functions of ubiquitin proteasome pathway components outside the cell. Ongoing biochemical and proteome analyses are aimed to define how the intracellular ubiquitin proteasome system is regulated in response to tissue damage and infection, and to understand its contribution to the development of hypermetabolism, protein wasting and disturbed cell function which frequently occur in response to severe trauma, shock and sepsis in patients. These studies are expected to lead to the identification of new molecular targets for therapeutic intervention. Furthermore, recent studies by Dr. Majetschak’s laboratory identified extracellular ubiquitin as a molecule with profound anti-inflammatory properties in-vitro and in-vivo. We showed that extracellular ubiquitin is involved in the regulation of leukocyte function after trauma and sepsis in patients and that ubiquitin’s in-vivo effects can be used therapeutically. Current studies are aimed to further delineate its therapeutic applicability and to identify its molecular mechanism of action.

 

Representative Publications:

View a partial list of Dr. Majetschak's publications through the National Library of Medicine's PubMed online database.